Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026)
Fulcrum Therapeutics (FULC) reported Return on Capital Employed of 24.97% for Q1 2026, down 1985.0% year-over-year from 1.32% in Q1 2025, and up 18.26% quarter-over-quarter from 30.54% in Q4 2025.
Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 8 years of Return on Capital Employed data on file, last reported at 24.97% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 24.97%, down 1985.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.97% (down 1985.0% YoY), and the FY2025 annual result was 28.21%, down 1939.0% from the prior year.
- Return on Capital Employed climbed to 24.97% in Q1 2026 per FULC's latest filing, from 30.54% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 5.12% in Q1 2025 and troughed at 56.33% in Q2 2022.
- A 5-year average of 34.37% and a median of 38.77% in 2025 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 4289 bps in 2025 and fell as far as 2758 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 51.04% in 2022, then advanced by 15 bps to 43.46% in 2023, then jumped by 81 bps to 8.46% in 2024, then plunged by 261 bps to 30.54% in 2025, then rose by 18 bps to 24.97% in 2026.
- Business Quant data shows FULC's Return on Capital Employed at 24.97% in Q1 2026, 30.54% in Q4 2025, and 38.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -24.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.97% |
| Dec 31, 2025 | -30.54% |
| Sep 30, 2025 | -38.77% |
| Jun 30, 2025 | -37.38% |
| Mar 31, 2025 | -5.12% |
| Dec 31, 2024 | -8.46% |
| Sep 30, 2024 | -11.19% |
| Jun 30, 2024 | -13.07% |
| Mar 31, 2024 | -48.01% |
| Dec 31, 2023 | -43.46% |
| Sep 30, 2023 | -40.16% |
| Jun 30, 2023 | -36.35% |
| Mar 31, 2023 | -44.13% |
| Dec 31, 2022 | -51.04% |
| Sep 30, 2022 | -52.29% |
| Jun 30, 2022 | -56.33% |
| Mar 31, 2022 | -43.00% |
| Dec 31, 2021 | -35.85% |
| Sep 30, 2021 | -42.75% |
| Jun 30, 2021 | -59.05% |